Logo

YDES

YD Bio Limited Ordinary Shares

YDES

YD Bio Limited Ordinary Shares • NASDAQ
$11.53 ▲ 9.60% (+1.01)
Market Cap $813.11 M
52w High $25.00
52w Low $5.30
Dividend Yield 0%
P/E -576.5
Volume 49.92K
Outstanding Shares 70.52M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $389.191K ▲ $-2.215M ▲ 0% $-0.65 ▲ $-2.216M ▲
Q1-2025 $0 $353.819K ▼ $-3.368M ▼ 0% $-0.98 ▼ $-3.366M ▼
Q4-2024 $0 $381.288K ▲ $417.791K ▼ 0% $0.1 ▼ $417.791K ▼
Q3-2024 $0 $260.083K ▼ $2.19M ▼ 0% $0.54 ▼ $2.178M ▼
Q2-2024 $0 $537.407K $17.104M 0% $4.05 $17.11M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $6.312K ▲ $2.951M ▼ $19.002M ▲ $-16.05M ▼
Q1-2025 $403 ▼ $3.516M ▼ $16.762M ▲ $-13.245M ▼
Q4-2024 $3.132M ▲ $6.864M ▼ $273.98K ▼ $6.59M ▲
Q3-2024 $0 ▼ $10.771M ▲ $13.64M ▼ $-2.869M ▲
Q2-2024 $39.97K $10.692M $15.75M $-5.059M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-2.215M ▲ $-298.19K ▲ $557.484K ▼ $-253.385K ▲ $5.909K ▲ $-298.19K ▲
Q1-2025 $-3.368M ▼ $-490.407K ▼ $7.284M ▲ $-6.895M ▼ $-101.271K ▼ $-490.41K ▼
Q4-2024 $417.791K ▼ $-365.649K ▼ $168.386K ▲ $298.935K ▲ $101.672K ▲ $-365.65K ▼
Q3-2024 $2.19M ▼ $-21.568K ▲ $-62.56K ▼ $44.16K ▲ $-39.968K ▼ $-21.57K ▲
Q2-2024 $17.104M $-592.517K $3.06M $-2.432M $35.483K $-592.52K

Five-Year Company Overview

Income Statement

Income Statement YD Bio looks like a classic early-stage biotech: essentially no commercial revenue yet and results driven by research spending and one‑off items rather than steady business activity. Reported earnings per share jump around from year to year, which likely reflects accounting adjustments and small base effects rather than fundamental profit strength. Overall, this is a pre‑revenue, loss‑making profile where the financial story is about investment in science, not current profitability.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small pool of assets and equity and no visible use of debt. This suggests the company has been funded mainly by shareholders rather than lenders and is still operating at a relatively small scale. The modest asset base limits financial flexibility and underscores how dependent the company likely is on future capital raises to support its pipeline and commercial plans.

Cash Flow

Cash Flow Reported cash flow is essentially flat, which is more a sign of limited scale and disclosure detail than of financial strength. As a clinical‑stage biotech, the business is almost certainly consuming cash to fund research, regulatory work, and early commercial activities, even if the table shows little movement. Future periods will likely show more meaningful cash outflows as clinical trials, manufacturing, and commercialization efforts ramp up, making access to new funding an important consideration.

Competitive Edge

Competitive Edge Competitively, YD Bio is trying to stand out with a dual focus on blood‑based cancer diagnostics and regenerative eye therapies, both of which target areas with high unmet medical need. Its partnerships with specialized labs and biotech collaborators give it access to U.S. testing infrastructure and ophthalmology know‑how that would be difficult to build alone. Patent protection and early U.S. regulatory clearances for certain eye products help create some barriers to entry, but the firm still faces intense competition from much larger diagnostics and biotech players, and its small scale makes execution risk meaningful.

Innovation and R&D

Innovation and R&D Innovation is at the core of this company. On one side, it is developing blood tests based on DNA methylation patterns to detect and monitor cancers in a non‑invasive way, including breast and pancreatic cancers. On the other side, it is advancing stem cell–derived exosome therapies and related eye care products for serious ocular conditions, supported by regulatory filings that lay groundwork for future drug development. Most of this work remains in the clinical and pre‑commercial phase, so scientific success, regulatory progress, and clinical trial results are critical uncertainties for the long term.

Summary

Overall, YD Bio is a small, research‑driven biotech with almost no current revenue, a thin balance sheet, and an early‑stage financial profile. Its appeal rests on a focused but diversified pipeline across cancer diagnostics and ophthalmology, backed by patents, partnerships, and some initial regulatory wins in the U.S. The main opportunities lie in turning its technologies into approved, widely used products; the main risks are scientific, regulatory, and funding‑related, as the company will likely need substantial additional capital and clear clinical successes to realize its potential.

NEWS

November 24, 2025 · 9:00 AM UTC

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Read more

November 5, 2025 · 8:30 AM UTC

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

Read more

October 20, 2025 · 10:20 AM UTC

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Read more

October 10, 2025 · 8:37 AM UTC

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Read more

September 30, 2025 · 5:25 PM UTC

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

Read more